Recent News

• 09.17.2025 - Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 09.17.2025 - Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 09.10.2025 - Pulse Biosciences’ nPulse™ Technology to be Featured at the American Thyroid Association 2025 Annual Meeting
• 09.10.2025 - Pulse Biosciences’ nPulse™ Technology to be Featured at the American Thyroid Association 2025 Annual Meeting
• 09.08.2025 - Pulse Biosciences Announces FDA IDE Approval to Initiate its nsPFA Cardiac Surgery System Study for the Treatment of Atrial Fibrillation
• 09.08.2025 - Pulse Biosciences Announces FDA IDE Approval to Initiate its nsPFA Cardiac Surgery System Study for the Treatment of Atrial Fibrillation
• 09.04.2025 - Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 09.04.2025 - Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 09.02.2025 - Pulse Biosciences Announces First Successful Procedures in PRECISE Benign Thyroid Nodule (BTN) Study
• 09.02.2025 - Pulse Biosciences Announces First Successful Procedures in PRECISE Benign Thyroid Nodule (BTN) Study

Recent Filings

• 09.15.2025 - 4 Statement of changes in beneficial ownership of securities
• 09.12.2025 - 4 Statement of changes in beneficial ownership of securities
• 09.11.2025 - 144 Report of proposed sale of securities
• 09.08.2025 - 8-K Current report
• 09.08.2025 - EX-99.1 EX-99.1
• 09.03.2025 - DEF 14A Other definitive proxy statements
• 09.02.2025 - EX-99.1 EX-99.1
• 09.02.2025 - 8-K Current report